This key production facility helped double Thermo Fisher’s commercial capacity for viral vectors. The increase in production supported the company in meeting growing demand for the development and manufacturing of gene therapies and vaccines. The estimated investment for the expansion was $180 million.

The Plainville site includes:

• - A pilot lab for process development, process transfer, and scale-up

• - 11 cGMP production areas for active pharmaceutical ingredients (APIs)

• - 2 cGMP production areas for finished drug products

• - Fully equipped quality control (QC) laboratories

• - An in-house engineering lab for the development of turnkey production systems, facilitating customer transitions to commercial operations

The facility additionally offers:

• - Cell culture platforms

• - Cleaning platforms

• - Analytical testing and QC capabilities

• - Aseptic filling and finishing services

The new Plainville facility complements Thermo Fisher’s production capacity at other key sites:

• - Lexington, Massachusetts

• - Cambridge, Massachusetts

• - Alachua, Florida